Karyopharm Therapeutics | Zobowiązania





Zobowiązania Zmiana Data
AbbVie USD 43.29B 3.9B 2025-12
Abbott USD 16.5B 1.91B 2025-12
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
BioCryst Pharmaceuticals USD 190.24M 13.08M 2025-09
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Eli Lilly USD 35.23B 4.91B 2025-12
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Incyte USD 1.52B 176.44M 2025-12
J&J USD 54.13B 3.26B 2025-12
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
MacroGenics USD 44.47M 5.47M 2025-09
Merck USD 28.63B 2.59B 2025-09
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Novartis USD 32B 286M 2025-09
Novartis USD 32B 286M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Takeda JPY 2.61T 470.53B 2025-12
Tectonic Therapeutic USD 9.37M 1.99M 2025-09
TG Therapeutics USD 153.76M 3.05M 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Xencor USD 95.91M 9.42M 2025-12


Karyopharm Therapeutics Zobowiązania - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2026.